<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158405</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 1269 TRIVACAN</org_study_id>
    <nct_id>NCT00158405</nct_id>
  </id_info>
  <brief_title>Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)</brief_title>
  <official_title>Multicentric Randomised Controlled Trial Assessing the Efficacy of Two Strategies of Structured Treatment Interruption of Highly Active Antiretroviral Therapy (HAART) Compared With a Continuous HAART in HIV- Infected Adults in Abidjan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interrupting HAART during limited periods of time (&quot;structured treatment interruption : STI&quot;)
      could entail benefits (better long term tolerance, lower drug-induced viral resistance, lower
      cost) but also concomitant risks (lower efficacy, higher drug-induced viral resistance). At
      present, the benefit/risk ratio of STI is unclear. Several STI trials are in progress in
      industrialised countries. This trial aim at assessing the benefits and risks of two different
      STI strategies in West Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the non-inferiority of two strategies of structured
      treatment interruption (STI) of highly active antiretroviral treatment (HAART) compared with
      a continuous HAART.

      It's a multicentric open labeled randomised non-inferiority trial, which takes place in 5
      health care centres in Abidjan, the economic capital city of Cote d'Ivoire

      The trial was designed in two phases :

        1. Pre-randomisation phase : 840 HAART-naive HIV-infected adults start the following
           continuous HAART regimen: zidovudine-lamivudine in combination with

             -  preferably efavirenz, for HIV-1 infected men, and HIV-1 infected women with an
                effective contraception and no history of nevirapine-containing p-MTCT (prevention
                of mother to child transmission);

             -  ritonavir-indinavir, for HIV-2 infected patients, women not desiring contraception,
                and women with a past history of p-MTCT with nevirapine.

        2. Trial phase : After at least six months on continuous HAART in the pre-randomisation
           phase, patients who meet success criteria (CD4 count over 350/mm3, undetectable viral
           load, absence of current opportunistic infection) are randomised into three arms :

             -  Arm 1: Continuous HAART (1 of 6 patients)

             -  Arm 2: Fixed STI strategy (3 of 6 patients): immutable periods of 2 months on HAART
                / 4 months off HAART

             -  Arm 3: CD4-guided STI strategy (2 of 6 patients): unlimited interruption of HAART,
                and then re-introduction/re-interruption guided by the evolution of the CD4 count.

      Following the DSMB recommendation, the arm 3 has been discontinued in october 2005. The trial
      is continuing for patients in the arms 1 and 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the non-inferiority at 24 months of two STI strategies of HAART compared with a continuous HAART in terms of :</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with CD4 count over 350 per mm3</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe morbidity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare at 24 months two STI strategies of HAART with a continuous HAART in terms of :</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV resistance to antiretroviral drugs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">840</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Structured Treatment Interruption</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (ZDV)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine (3TC)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz (EFV)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir (NRV)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir (IDV)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  18 years old or more

          -  CD4 count between 150 and 350 per mm3 (or CD4 percentage between 12.5 and 20 percent)

          -  no past history of curative antiretroviral therapy

          -  residence in Abidjan

        Exclusion Criteria:

          -  pregnancy

          -  severe renal failure

          -  severe hepatic failure

          -  severe neuropsychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Anglaret, MD</last_name>
    <role>Study Director</role>
    <affiliation>Unité INSERM 593, Université Victor Segalen Bordeaux 2</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Danel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Programme PACCI, Abidjan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Salamon, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Unité INSERM 593, Université Victor Segalen Bordeaux 2</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Bissagnene, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Treichville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Prise en Charge et de Formation ACONDA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Intégré de Recherches Biocliniques d'Abidjan</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales, CHU de Treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Soins Ambulatoires et de Conseil, CHU de Treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <reference>
    <citation>Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Antivir Ther. 2005;10(5):615-24.</citation>
    <PMID>16152755</PMID>
  </reference>
  <results_reference>
    <citation>Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholié S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 trial group. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006 Jun 17;367(9527):1981-9.</citation>
    <PMID>16782488</PMID>
  </results_reference>
  <results_reference>
    <citation>Danel C, Moh R, Chaix ML, Gabillard D, Gnokoro J, Diby CJ, Toni T, Dohoun L, Rouzioux C, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 Trial Group. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis. 2009 Jan 1;199(1):66-76. doi: 10.1086/595298.</citation>
    <PMID>18986246</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>December 29, 2008</last_update_submitted>
  <last_update_submitted_qc>December 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2008</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Structured treatment interruption</keyword>
  <keyword>HAART</keyword>
  <keyword>Sub-saharian africa</keyword>
  <keyword>Treatment Interruption</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

